ReviewBreast cancer : basic and clinical research2026
Impact of Distinct Molecular and Immunological Features of Breast Cancer on the Effectiveness of Therapies in Ghana.
Review in Breast cancer : basic and clinical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer (BC) is a serious public health concern in sub-Saharan Africa, with Ghana incurring a staggering 5026 cases and 2369 deaths in 2022. The insufficiency of accurate epidemiological information, limited access to health care, late diagnoses, and insufficient screening procedures hinder policy implementation. While numerous treatment methods, such as chemotherapy, radiation, and immunotherapy, exist, patients with BC respond differently. The variation in response can be accounted for by a combination of genetic, environmental, and socioeconomic factors specific to the Ghanaian population. This review examines the unique molecular and immunologic characteristics of BC in Ghana and their implications for therapeutic effectiveness in personalized treatment. Precision medicine is suggested as imperative in the design of biomarker-guided therapies to consider the BC molecular heterogeneity that is prevalent among Ghanaian patients. However, there is still a challenge of late-stage diagnosis due to insufficient diagnostic infrastructure. Early detection efforts through investment in next-generation sequencing and health care training are imperative. Besides, immune checkpoint inhibitors show promising therapeutic utility in triple-negative breast cancer (TNBC), and clinical trials in the Ghanaian population should be considered. This article emphasizes the need for community education to counteract misconceptions and ensure timely health care-seeking behaviours. To minimize mortality rates and improve patient care for BC in Ghana, a concerted approach through research funding, policy reform, and collaborative stakeholder engagement is imperative, in addition to advancements in diagnostics and therapeutics in the local context.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.